Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer. Decipher Prostate Metastatic Genomic Classifier has been launched for use in patients ...

New NCCN Guidelines Recommend Use of Veracyte's Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men After Radical Prostatectomy ...

Published data suggest Veracyte's Decipher Prostate Biopsy genomic classifier may help guide the use of active surveillance in prostate cancer ...

The researchers retrospectively evaluated whether the initial Decipher scores for 133 men on active surveillance were correlated with the incidence of Gleason grade group upgrade over time.

Genomic cancer testing company Veracyte is moving to acquire Decipher Biosciences in a $600 million deal, with the goal of broadening its diagnostic rea ...

Veracyte To Acquire Decipher Biosciences For $600 Mln Cash, Stock - Quick Facts February 03, 2021 — 07:39 am EST Written by RTTNews.com for RTTNews -> ...